Fresh analysis reveals that people who come off new weight-loss injections like semaglutide or tirzepatide tend to recover reduced body mass far faster than those who end traditional diet and exercise programs.
Findings released in a major medical journal demonstrates that while overweight people can lose about a fifth of their total mass while undergoing treatment, the mass is regained at an average rate of nearly a kilo each month upon discontinuation.
"Users using these medications must be aware of the risk of fast rebound weight gain when the medication ends," stated researcher Dr. Susan Jebb.
That rate of recovery implies a return to pre-treatment mass in about one and a half years.
Analyzing Approaches
The research, which examined dozens of studies involving thousands of patients, compared the results of the injectable medications with other pills.
Scientists emphasize that individuals who lose weight through lifestyle changes alone generally see a slower creep back—around 0.1 kg a month—post-intervention.
The Reason for the Quick Rebound
Doctors suggest the mode of action of the drugs is key to understanding the amplified rebound.
The injections imitate a natural hormone called GLP-1, which moderates hunger.
"Long-term administration of the hormone concentrations far above than the body's typical production may cause the body to generate a reduced amount of its endogenous hormone, and could lessen responsiveness to its actions," noted Dr. Adam Collins, a nutrition expert.
"Withdrawal of this GLP-1 'fix' means hunger is no longer kept in check, making overeating far more likely."
An Ongoing Condition?
Health authorities advise the jabs for individuals with weight-linked health risks, alongside prescribed lifestyle changes.
Many experts say that, due to the high risk of relapse, the treatment is often life-long.
This view is echoed by drug manufacturers, who note that the results "highlight the persistent character of excess weight," akin to managing conditions like diabetes.
Patient Experiences
Users who have discontinued the medication describe a sudden resurgence of hunger.
"It was like a switch flipping and you're instantly ravenous," recalled a patient.
The struggle is worsened if patients have not established sustainable dietary or behavioural changes during therapy.
Growing Use
Survey data suggest that a significant number of adults in the UK have tried these injections in the last 12 months, with desire continuing to grow.
- Adoption is greater among females than males.
- The middle-aged demographic shows the greatest level of interest.
- Many obtain the medications through private healthcare rather than the NHS.
Ultimately, researchers emphasize that while GLP-1 drugs are effective tools for weight loss, they are not a standalone cure and lasting health benefits hinges on integrated behavioural management.
